KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Other Gross PP&E Adjustments (2016 - 2026)

Alnylam Pharmaceuticals filings provide 16 years of Other Gross PP&E Adjustments readings, the most recent being -$189.3 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 4.02% to -$189.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$189.3 million through Mar 2026, up 4.02% year-over-year, with the annual reading at $606.6 million for FY2025, 7.93% up from the prior year.
  • Other Gross PP&E Adjustments hit -$189.3 million in Q1 2026 for Alnylam Pharmaceuticals, down from $606.6 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $606.6 million in Q4 2025 and bottomed at -$228.8 million in Q1 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$29.4 million, with a median of -$196.4 million recorded in 2024.
  • The largest annual shift saw Other Gross PP&E Adjustments rose 17.57% in 2022 before it dropped 0.9% in 2025.
  • Alnylam Pharmaceuticals' Other Gross PP&E Adjustments stood at $462.0 million in 2022, then grew by 14.35% to $528.2 million in 2023, then rose by 6.39% to $562.0 million in 2024, then grew by 7.93% to $606.6 million in 2025, then crashed by 131.21% to -$189.3 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Other Gross PP&E Adjustments are -$189.3 million (Q1 2026), $606.6 million (Q4 2025), and -$191.4 million (Q3 2025).